Search Results - "TUTT, Alison L"

Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration by Lunnon, Katie, Teeling, Jessica L, Tutt, Alison L, Cragg, Mark S, Glennie, Martin J, Perry, V Hugh

“…Chronic neurodegeneration is a major worldwide health problem, and it has been suggested that systemic inflammation can accelerate the onset and progression of…”
Get full text

CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses by Castro, Fernanda V.V, Tutt, Alison L, White, Ann L, Teeling, Jessica L, James, Sonya, French, Ruth R, Glennie, Martin J

“…The magnitude and quality of T cell responses generated when Ag is targeted to receptors on DC is influenced by both the specific receptor targeted and its…”
Get full text

Domain binding and isotype dictate the activity of anti-human OX40 antibodies by Griffiths, Jordana, Hussain, Khiyam, Smith, Hannah L, Sanders, Theodore, Cox, Kerry L, Semmrich, Monika, Mårtensson, Linda, Kim, Jinny, Inzhelevskaya, Tatyana, Penfold, Chris A, Tutt, Alison L, Mockridge, C Ian, Chan, HT Claude, English, Vikki, French, Ruth F, Teige, Ingrid, Al-Shamkhani, Aymen, Glennie, Martin J, Frendeus, Bjorn L, Willoughby, Jane E, Cragg, Mark S

“…BackgroundPrevious data suggests that anti-OX40 mAb can elicit anti-tumor effects in mice through deletion of Tregs. However, OX40 also has powerful…”
Get full text

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses by Taraban, Vadim Y., Rowley, Tania F., O'Brien, Lyn, Chan, H. T. Claude, Haswell, Linsey E., Green, Michael H. A., Tutt, Alison L., Glennie, Martin J., Al‐Shamkhani, Aymen

“…This study addresses the relative importance of CD134 (OX40) and CD137 (4‐1BB) in the costimulation of CD4+ and CD8+ T cells under comparable conditions of…”
Get full text

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody by White, Ann L, Chan, H T Claude, Roghanian, Ali, French, Ruth R, Mockridge, C Ian, Tutt, Alison L, Dixon, Sandra V, Ajona, Daniel, Verbeek, J Sjef, Al-Shamkhani, Aymen, Cragg, Mark S, Beers, Stephen A, Glennie, Martin J

“…A high activatory/inhibitory FcγR binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and…”
Get full text

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking by Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.

“…CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells…”
Get full text

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells by Cragg, Mark S., Bayne, Mike B., Tutt, Alison L., French, Ruth R., Beers, Stephen, Glennie, Martin J., Illidge, Timothy M.

“…The chimeric anti-CD20 monoclonal antibody (mAb), rituximab, is an established part of the management of many non-Hodgkin lymphomas. The in vivo action of…”
Get full text

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms by Simpson, Alexander P., Roghanian, Ali, Oldham, Robert J., Chan, H.T. Claude, Penfold, Christine A., Kim, Hyung J., Inzhelevskaya, Tatyana, Mockridge, C. Ian, Cox, Kerry L., Bogdanov, Yury D., James, Sonya, Tutt, Alison L., Rycroft, Daniel, Morley, Peter, Dahal, Lekh N., Teige, Ingrid, Frendeus, Björn, Beers, Stephen A., Cragg, Mark S.

“…Many therapeutic antibodies deplete target cells and elicit immunotherapy by engaging activating Fc gamma receptors (FcγRs) on host effector cells. These…”
Get full text

Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo by Tipton, Thomas R.W., Mockridge, C. Ian, French, Ruth R., Tutt, Alison L., Cragg, Mark S., Beers, Stephen A.

Get full text

Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors by Tutt, Alison L, James, Sonya, Laversin, Stéphanie A, Tipton, Thomas R W, Ashton-Key, Margaret, French, Ruth R, Hussain, Khiyam, Vaughan, Andrew T, Dou, Lang, Earley, Alexander, Dahal, Lekh N, Lu, Chen, Dunscombe, Melanie, Chan, H T Claude, Penfold, Christine A, Kim, Jinny H, Potter, Elizabeth A, Mockridge, C Ian, Roghanian, Ali, Oldham, Robert J, Cox, Kerry L, Lim, Sean H, Teige, Ingrid, Frendéus, Bjorn, Glennie, Martin J, Beers, Stephen A, Cragg, Mark S

“…FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through…”
Get full text

Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB by Stopforth, Richard J, Oldham, Robert J, Tutt, Alison L, Duriez, Patrick, Chan, H T Claude, Binkowski, Brock F, Zimprich, Chad, Li, Dun, Hargreaves, Philip G, Cong, Mei, Reddy, Venkat, Leandro, Maria J, Cambridge, Geraldine, Lux, Anja, Nimmerjahn, Falk, Cragg, Mark S

“…Fc γ receptors (FcγR) are involved in multiple aspects of immune cell regulation, are central to the success of mAb therapeutics, and underpin the pathology of…”
Get full text

Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells by ROBERTS, Drew J, FRANKLIN, Nathan A, KINGETER, Lara M, YAGITA, Hideo, TUTT, Alison L, GLENNIE, Martin J, BULLOCK, Timothy N. J

“…The immune response to the tumor can be enhanced by targeting costimulatory molecules on T cells. As the CD70-CD27 costimulatory axis plays an important role…”
Get full text

Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation by French, Ruth R., Taraban, Vadim Y., Crowther, Graham R., Rowley, Tania F., Gray, Juliet C., Johnson, Peter W., Tutt, Alison L., Al-Shamkhani, Aymen, Glennie, Martin J.

“…Growing evidence points to the potential of agonistic anti-CD40 mAbs as adjuvants for vaccination against cancer. These appear to act by maturing dendritic…”
Get full text

Enhanced FcαRI‐mediated neutrophil migration towards tumour colonies in the presence of endothelial cells by Otten, Marielle A., Bakema, Jantine E., Tuk, Cornelis W., Glennie, Martin J., Tutt, Alison L., Beelen, Robert H.J., van de Winkel, Jan G. J., van Egmond, Marjolein

“…Neutrophils potently kill tumour cells in the presence of anti‐tumour antibodies in vitro. However, for in vivo targeting, the neutrophils need to extravasate…”
Get full text

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization by Williams, Emily L, Tutt, Alison L, Beers, Stephen A, French, Ruth R, Chan, Claude H T, Cox, Kerry L, Roghanian, Ali, Penfold, Christine A, Butts, Cherié L, Boross, Peter, Verbeek, J Sjef, Cragg, Mark S, Glennie, Martin J

“…Genetic deficiency of the inhibitory Fc receptor, FcγRIIB (CD32b), has been shown to augment the activity of activatory FcγR and promote mAb immunotherapy. To…”
Get full text

Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B) by Williams, Emily L., Tutt, Alison L., French, Ruth R., Chan, H. T. Claude, Lau, Betty, Penfold, Christine A., Mockridge, C. Ian, Roghanian, Ali, Cox, Kerry L., Verbeek, J. Sjef, Glennie, Martin J., Cragg, Mark S.

“…Fc receptors (FcRs) play a key role in regulating and coordinating responses from both innate and adaptive arms of the immune system. The inhibitory Fc gamma…”
Get full text

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts by CHAN, H. T, HUGHES, David, FRENCH, Ruth R, TUTT, Alison L, WALSHE, Claire A, TEELING, Jessica L, GLENNIE, Martin J, CRAGG, Mark S

“…Rituximab is routinely used for the treatment of neoplasia, although the mechanism of action remains uncertain. In the current study, CD20-induced apoptosis…”
Get full text

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help by Glennie, Martin J, French, Ruth R, Chan, H.T. Claude, Tutt, Alison L

“…CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against…”
Get full text

Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant by White, Ann L., Tutt, Alison L., James, Sonya, Wilkinson, Kevin A., Castro, Fernanda V. V., Dixon, Sandra V., Hitchcock, Jessica, Khan, Mahmood, Al‐Shamkhani, Aymen, Cunningham, Adam F., Glennie, Martin J.

“…Summary In this study, we investigated the mouse dendritic cell (DC) receptor, complement receptor 4 (CR4; CD11c/CD18), as an immunotarget for triggering…”
Get full text

T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody by Tutt, Alison L, O'Brien, Lyn, Hussain, Akmal, Crowther, Graham R, French, Ruth R, Glennie, Martin J

“…In this study we demonstrate that treatment with anti-CD40 mAb eradicates a range of mouse lymphomas (BCL(1), A31, A20, and EL4), but only when used against…”
Get full text